MARKET NEWS

Avalon GloboCare Announces Breakthrough in Identifying Human Angiogenic Exosomes/Extracellular Vesicles (EV) Derived From Endothelial Cells
Eton Pharmaceuticals Enters Into License Agreement for Two Branded Hospital Product Candidates
Aduro Announces First Patient Dosed in Phase 1 Study
Genocea Announces Private Placement Financing of Up to $39 Million
Despite Recent Setbacks, the Ophthalmology Market Still Offers Vast Potential
Active Biotech's Partner NeoTX Enters Clinical Collaboration With AstraZeneca

  FEATURED EDITORIAL

  COMPANY PROFILE

Cambrex is the leading small molecule company that provides drug substance and drug product services across the entire drug lifecycle. Driven by passion, our pharmaceutical products, expertise and technologies accelerate our customers’ small molecule therapeutics into markets across the world. Click here for more.

Metrics Contract Services is a full service pharmaceutical development and manufacturing organization serving clients worldwide. We deliver proven scientific and operational excellence for oral dosage forms. Today, as a subsidiary of Mayne Pharma Group, we offer clients more resources and capabilities than ever before. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Passage Bio Launches With 5.5 Million Financing to Develop AAV-Delivered Therapeutics

Passage Bio Launches With $115.5 Million Financing to Develop AAV-Delivered Therapeutics

Passage Bio recently debuted with a $115.-million Series A financing led by OrbiMed Advisors and joined by Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital and Lilly Asia Ventures.

DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical

DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical

DiaMedica Therapeutics Inc. recently announced it has initiated dosing patients with chronic kidney disease (CKD) in a Phase Ib clinical study evaluating DM199.

Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License: Triggers Milestone

Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License: Triggers Milestone

Codexis, Inc. recently announced that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialization of Codexis’ novel, orally delivered enzyme CDX-6114 for the management of phenylketonuria (PKU), an orphan metabolic disorder.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

February 27 – ODT/Fast Dissolve
March 6 – Transdermal/Topical Delivery